ライフサイエンスコーパス: absenteeism

1 c impacts resulting from hospitalization and absenteeism.

2 ure of asthma-associated morbidity is school absenteeism.

3 t presentation to the school nurse or during absenteeism.

4 of SLV on laboratory-confirmed influenza and absenteeism.

5 ovements in management methods reduce school absenteeism.

6 nt-perceived ill health, and school problems/absenteeism.

7 pressure on quality of life, mood, and work absenteeism.

8 levels of health care utilization, and work absenteeism.

9 care use and indirect costs, chiefly through absenteeism.

10 .5%; adjusted OR, 1.25 [95% CI, 1.09-1.43]), absenteeism (26.0% vs 20.9%; adjusted OR, 1.23 [95% CI,

11 nge from baseline [SE]) relative to placebo: absenteeism (-3.5 [0.87], P < .001; -2.6 [0.84], P = .00

12 Reasons for not vaccinating included absenteeism (6.3%) and parent refusal (6.7%).

13 .006 to 0.03] L/yr, respectively), and lower absenteeism (-8% [95% CI, -16.0 to -0.7%]), with stronge

14 gnificant morbidity and high rates of school absenteeism, along with excessive costs for the patient

15 ed with increased respiratory-related school absenteeism among children, especially those with asthma

16 itive employees and associated reductions in absenteeism and benefit payments lead to cost savings co

17 truction, and asthma-related school and work absenteeism and hospital admissions obtained during nine

18 mentation, alone or in combination, affected absenteeism and illness in iron-deficient schoolchildren

19 own risk factor for poorer health, increased absenteeism and lower work performance.

20 that are feasible to monitor, such as school absenteeism and national ILI surveillance system.

21 In the United States, related absenteeism and poor job performance cost $148 billion a

22 Indirect costs (absenteeism and presenteeism [productivity lost in the w

23 MTX, CZP plus MTX significantly reduced work absenteeism and presenteeism among patients working outs

24 nts with CHC GT1 in the ION trials exhibited absenteeism and presenteeism impairments of 2.57% and 7.

25 rials achieved SVR; these patients exhibited absenteeism and presenteeism impairments of 2.62% (P = 0

26 euro55 and euro151 billion per annum due to absenteeism and presenteeism, that is, euro2405 per untr

27 atient resource utilisation and the costs of absenteeism and replacement of sick workers.

28 ntly improves school performance and reduces absenteeism and tardiness.

29 tween HCV infection, productivity, increased absenteeism, and higher healthcare benefit costs.

30 y, as shown by increased use of health care, absenteeism, and reduced workplace productivity.

31 infection, incidence of infection-associated absenteeism, and scores on the physical and mental healt

32 tings due to reductions in healthcare costs, absenteeism, and staff turnover.

33 chronotype on grades was similar to that of absenteeism, and that late chronotypes were more often a

34 itive to assumptions regarding incidence and absenteeism, ART is cost-saving under considerable param

35 lementation should reduce significant school absenteeism as well as complications seen last year incl

36 sociated with improved FeNO, FVC growth, and absenteeism, but these findings were primarily restricte

37 Asthma is a leading cause of school absenteeism, but this absenteeism is not equally distrib

38 on, changed fuel/technologies likely reduced absenteeism by more than 14 million/yr.

39 Employee absenteeism caused by flu infection costs hundreds of mi

40 Parental consent for sharing absenteeism data was obtained for 937 (57%) of 1,640 stu

41 urgery; 23,814 were employees with workplace absenteeism data.

42 enza vaccination was associated with reduced absenteeism due to fever or cough illness, but not absen

43 The vaccine efficacy for preventing school absenteeism due to respiratory illness during the period

44 ched euro1772.90 (presenteeism, euro1682.71; absenteeism, euro90.19).

45 Rates of school absenteeism for any cause (based on school records) were

46 eeism due to fever or cough illness, but not absenteeism for other reasons.

47 Health plan spending and workplace absenteeism from 14 days before through 352 days after t

48 ainly in terms of productivity losses due to absenteeism from work.

49 ed symptoms of infection, symptom-associated absenteeism, health care use, and impact on daily activi

50 e, asthma status, and illness-related school absenteeism in a cohort of 1,932 fourth-grade schoolchil

51 f participant-reported infection and related absenteeism in a sample of participants with type 2 diab

52 Illness-related school absenteeism is a measure of a broad spectrum of adverse

53 eading cause of school absenteeism, but this absenteeism is not equally distributed among those with

54 oductive capacity (99% vs 87%; P<.001), less absenteeism (losses = $24 vs $115 per worker per month;

55 owth, health care attention seeking, daycare absenteeism, or other health variables.

56 omic consequences such as absence from work (absenteeism), particularly reduced productivity at work

57 saving and investment, worker productivity, absenteeism, premature mortality and medical costs.

58 This study was designed to compare absenteeism, productivity, and health cost between emplo

59 HPV vaccination did not increase absenteeism rates in selected schools.

60 School absenteeism rates prior to vaccination ranged from 8.1%

61 to employees leaving the workforce and when absenteeism rates were half of what data suggested.

62 ctiveness in schools have assessed all-cause absenteeism rather than laboratory-confirmed influenza.

63 re less sensitive to the value of the excess absenteeism threshold triggering the start of the interv

64 Infection-related absenteeism was also higher in the placebo group than in

65 rial serum samples were collected and school absenteeism was assessed.

66 st (13.0 days) and the rate of parental work absenteeism was highest (136 days per 100 children with

67 School absenteeism was seen in 11.8% of affected children.

68 oxide (FeNO), lung function (FEV1, FVC), and absenteeism were also collected monthly (1,768 visits).

69 The effects of ETS exposure on absenteeism were assessed by using stratified incidence

70 COVER-2 and UNCOVER-3, with the exception of absenteeism with ixekizumab Q4W in UNCOVER-2.